<DOC>
	<DOCNO>NCT00258284</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine together docetaxel work treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Capecitabine Docetaxel Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient androgen-independent metastatic adenocarcinoma prostate treat capecitabine docetaxel . Secondary - Determine toxicity regimen patient . - Determine progression-free survival , time treatment failure , overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive docetaxel IV 30 minute day 1 , 8 , 15 oral capecitabine twice daily day 5-18 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course therapy beyond CR After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 28 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Metastatic disease Androgenindependent disease Progressive disease , document ≥ 1 follow criterion : Rising prostatespecific antigen ( PSA ) despite androgen deprivation therapy antiandrogen withdrawal Demonstrates rise PSA trend 2 successive elevation ≥ 1 week apart Measurable disease progression Nonmeasurable disease progression , define follow : PSA ≥ 5 ng/mL New area bone metastases bone scan Serum testosterone ≤ 0.5 ng/mL ( castrate level ) Concurrent luteinizing hormonereleasing hormone agonist therapy require medically castrated patient PATIENT CHARACTERISTICS : Performance status Zubrod 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/ mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal Transaminases meeting 1 follow criterion : AST and/or ALT ≤ 2.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) normal AP ≤ 4 time ULN AST and/or ALT normal Renal Creatinine clearance ≥ 50 mL/min OR Creatinine ≤ 2 mg/dL Cardiovascular No congestive heart failure No second thirddegree heart block No myocardial infarction within past 3 month Other Fertile patient must use effective contraception 6 month completion study treatment No malignancy within past 2 year except adequately treated skin cancer cancer complete remission No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : Chemotherapy No prior chemotherapy metastatic disease Endocrine therapy See Disease Characteristics More 4 week since prior flutamide More 6 week since prior bicalutamide nilutamide Radiotherapy At least 4 week since prior radiotherapy Other At least 28 day since prior investigational drug prostate cancer No concurrent anticancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>